New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2013
16:21 EDTMYGNMyriad Genetics announces $200M stock repurchase program
Myriad announces that its Board of Directors has authorized a new $200 million stock repurchase program. "This decision is reflective of Myriad Genetics commitment to maintaining a balanced capital deployment strategy," said Jim Evans, Chief Financial Officer of Myriad Genetics, Inc. Repurchases under the $200 million authorization will be made through open market or privately negotiated purchases as determined by the Company's management. The amount and timing of stock repurchases will depend on business and market conditions, stock price, trading restrictions, acquisition activity and
News For MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 7, 2015
07:07 EDTMYGNMyriad Genetics, Tufts Health Plan sign agreement to cover Prolaris
Myriad Genetics announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris for members diagnosed with localized prostate cancer. Prolaris is the first and only biopsy test validated against prostate cancer specific mortality. Tufts Health Plan is a leading health plan in the Northeast with more than one million members. Tufts Health Plan's members will benefit from this agreement, which is designed to drive optimal treatment because men can confidently pursue active surveillance for tumors identified as being less aggressive with Myriad's extensively validated Prolaris combined score. Recent data show that many men realize no benefit from interventional treatment, and many suffer needlessly from the side effects associated with radical prostatectomy and radiation.
October 6, 2015
07:23 EDTMYGNAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use